Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.0029.03%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.11% | -29.56% | -32.22% | -17.26% | 33.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.11% | -29.56% | -32.22% | -17.26% | 33.48% |
| Operating Income | 45.11% | 29.56% | 32.22% | 17.26% | -33.48% |
| Income Before Tax | 53.19% | 17.72% | 39.13% | -0.35% | -631.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 53.19% | 17.72% | 39.13% | -0.35% | -631.17% |
| Earnings from Discontinued Operations | -- | -- | 100.00% | -- | 814.34% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.59% | 56.33% | 96.37% | 58.45% | 920.66% |
| EBIT | 45.11% | 29.56% | 32.22% | 17.26% | -33.48% |
| EBITDA | -- | -- | 302.93% | 38.22% | -73.13% |
| EPS Basic | 74.64% | 99.72% | 100.16% | 99.80% | 87.05% |
| Normalized Basic EPS | 74.39% | 97.94% | 99.41% | 99.07% | -106.05% |
| EPS Diluted | 74.64% | 99.72% | 100.16% | 99.80% | 87.05% |
| Normalized Diluted EPS | 74.39% | 97.94% | 99.41% | 99.07% | -106.05% |
| Average Basic Shares Outstanding | 82.82% | 3,878.52% | 10,397.35% | 10,653.94% | 8,672.42% |
| Average Diluted Shares Outstanding | 82.82% | 3,878.52% | 10,397.35% | 10,653.94% | 8,672.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |